内科理论与实践

内科理论与实践 >

2023 , Vol. 18 >Issue 05: 356 - 358

DOI: https://doi.org/10.16138/j.1673-6087.2023.05.010

病例报告

以认知行为异常为首发症状的真性红细胞增多症合并脑梗死1例

展开
  • 山西医科大学第三医院（山西白求恩医院 山西医学科学院 华中科技大学 同济医学院附属同济医院山西医院）神经内科，山西 太原 030032

收稿日期: 2023-03-01

  网络出版日期: 2024-01-26

收起

A case of polycythemia vera complicated with cerebral infarction with cognitive behavior abnormality as the first symptom

Expand

Received date: 2023-03-01

  Online published: 2024-01-26

Fold

本文引用格式

王金于, 上官丽娟, 史可, 闫卫红 . 以认知行为异常为首发症状的真性红细胞增多症合并脑梗死1例[J]. 内科理论与实践, 2023 , 18(05) : 356 -358 . DOI: 10.16138/j.1673-6087.2023.05.010

参考文献

[1] Asakura H. Thrombosis in myeloproliferative neoplasms[J]. Rinsho Ketsueki, 2018, 59(8): 1034-1041.
[2] 孙秉中. 真性红细胞增多症的诊断与治疗[C]. 中华医学会第十一次全国血液学学术会议论文集. 西安, 2010: 18-23.
[3] Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia[J]. Blood, 2016, 127(20): 2391-405.
[4] Spivak JL. Polycythemia vera[J]. Curr Treat Options Oncol, 2018, 19(2): 12.
[5] Falanga A, Marchetti M. Thrombotic disease in the myeloproliferative neoplasms[J]. Hematology Am Soc Hematol Educ Program, 2012, 2012: 571-81.
[6] Martin K. Risk factors for and management of MPN-associated bleeding and thrombosis[J]. Curr Hematol Malig Rep, 2017, 12(5): 389-396.
[7] Tefferi A, Elliott M. Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F[J]. Semin Thromb Hemost, 2007, 33(4): 313-320.
[8] Edelmann B, Gupta N, Schnoeder TM, et al. JAK2-V617F promotes venous thrombosis through β1/β2 integrin activation[J]. J Clin Invest, 2018, 128(10): 4359-4371.
[9] Wolach O, Sellar RS, Martinod K, et al. Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms[J]. Sci Transl Med, 2018, 10(436): eaan8292.
[10] Etheridge SL, Roh ME, Cosgrove ME, et al. JAK2V617F-positive endothelial cells contribute to clotting abnormalities in myeloproliferative neoplasms[J]. Proc Natl Acad Sci U S A, 2014, 111(6): 2295-2300.
[11] Iurlo A, Cattaneo D, Bucelli C, et al. New perspectives on polycythemia vera: from diagnosis to therapy[J]. Int J Mol Sci, 2020, 21(16): 5805.
[12] Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management[J]. Am J Hematol, 2020, 95(12): 1599-1613.
[13] Barbui T, Barosi G, Birgegard G, et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet[J]. J Clin Oncol, 2011, 29(6): 761-770.
[14] 中华医学会血液学分会白血病淋巴瘤学组. 真性红细胞增多症诊断与治疗中国专家共识(2016年版)[J]. 中华血液学杂志, 2016, 37(4): 265-268.
[15] How J, Hobbs G. Management issues and controversies in low-risk patients with essential thrombocythemia and polycythemia vera[J]. Curr Hematol Malig Rep, 2021, 16(5): 473-482.
[16] Marchioli R, Finazzi G, Landolfi R, et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera[J]. J Clin Oncol, 2005, 23(10): 2224-2232.
[17] Zwicker JI, Paranagama D, Lessen DS, et al. Hemorrhage in patients with polycythemia vera receiving aspirin with an anticoagulant: a prospective, observational study[J]. Haematologica, 2022, 107(5): 1106-1110.
[18] Vannucchi AM. Insights into the pathogenesis and management of thrombosis in polycythemia vera and essential thrombocythemia[J]. Intern Emerg Med, 2010, 5(3): 177-184.
[19] 中华医学会神经病学分会, 中华医学会神经病学分会脑血管病学组. 中国急性脑梗死后出血转化诊治共识2019[J]. 中华神经科杂志, 2019, 52(4): 252-265.
Options
文章导航

/

〈 〉